1. Lipoprotein-Associated Phospholipase A2 Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome
- Author
-
Hyuck Moon Kwon, Minhee Jo, Pil-Ki Min, Sung-Joo Lee, Myung-Hyun Kim, Jong-Kwan Park, Ji Hyun Yoon, Jeong-Hee Yang, Byoung Kwon Lee, Jong Youn Kim, Eui-Young Choi, Bum-Kee Hong, Hyemoon Chung, Se-Joong Rim, Young Won Yoon, and Jihyuk Rhee
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,Cardiac & Cardiovascular Systems ,Lp-PLA2 ,coronary atherosclerotic plaque instability ,Coronary Angiography ,acute coronary syndrome ,Angina Pectoris ,Risk Factors ,Internal medicine ,Medicine ,Humans ,Aged ,Aged, 80 and over ,Receiver operating characteristic ,biology ,business.industry ,Lipoprotein-associated phospholipase A2 ,C-reactive protein ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Plaque, Atherosclerotic ,Lipoproteins, LDL ,Stenosis ,C-Reactive Protein ,Logistic Models ,ROC Curve ,1-Alkyl-2-acetylglycerophosphocholine Esterase ,Multivariate Analysis ,biology.protein ,Cardiology ,Biomarker (medicine) ,biomarker ,lipids (amino acids, peptides, and proteins) ,Original Article ,Female ,business ,Biomarkers ,Lipoprotein - Abstract
Purpose Plasma lipoprotein-associated phospholipase A₂ (Lp-PLA₂) binds to low-density lipoprotein. The levels of Lp-PLA₂ reflect the plaque burden, and are upregulated in acute coronary syndrome (ACS). We investigated the diagnostic value of Lp-PLA2 levels and found that it might be a potential biomarker for ACS. Materials and methods We classified 226 study participants into three groups: patients without significant stenosis (control group), patients with significant stenosis with stable angina (SA group), and patients with ACS (ACS group). Results Lp-PLA₂ and high-sensitivity C-reactive protein (hs-CRP) levels were significantly greater in the ACS group than in the SA group (p=0.044 and p=0.029, respectively). Multivariate logistic regression analysis revealed that Lp-PLA₂ levels are significantly associated with ACS (odds ratio=1.047, p=0.013). The addition of Lp-PLA₂ to the ACS model significantly increased the global χ² value over traditional risk factors (28.14 to 35.602, p=0.006). The area under the receiver operating characteristic curve for Lp-PLA₂ was 0.624 (p=0.004). The addition of Lp-PLA₂ level to serum hs-CRP concentration yielded an integrated discrimination improvement of 0.0368 (p=0.0093, standard error: 0.0142) and improved the ability to diagnose ACS. Conclusion Lp-PLA₂ levels are related to plaque stability and might be a diagnostic biomarker for ACS.
- Published
- 2014